Ibrutinib

Definition

An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.

Also known as 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, IBRUTINIB, Imbruvica, PCI 32765, PCI-32765, PCI32765 — per NCIT

Also identified as

• ATC L01EL01 per RXNORM
• NCIT NCIT:C81934 per NCIT
• SCTID 710228002 per RXNORM
• SCTID 715598009 per RXNORM
• UNII 1X70OSD4VX per RXNORM

Indications

Organ Effects

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.